Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants. All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Crispr gene-editing technology has demonstrated its revolutionary potential in recent years: It has been used to treat rare diseases, to adapt crops to withstand the extremes of climate change, or even to change the color of a spider's web.

Despite recent advances in insulin preparations and technology, adjusting insulin remains an ongoing challenge for the majority of people with type 1 diabetes (T1D) and longstanding type 2 diabetes (T2D). In this study, we propose the Adaptive Basal-Bolus Advisor (ABBA), a personalised insulin treatment recommendation approach based on reinforcement learning for individuals with T1D and T2D, performing self-monitoring blood glucose measurements and multiple daily insulin injection therapy. We developed and evaluated the ability of ABBA to achieve better time-in-range (TIR) for individuals with T1D and T2D, compared to a standard basal-bolus advisor (BBA). The in-silico test was performed using an FDA-accepted population, including 101 simulated adults with T1D and 101 with T2D. An in-silico evaluation shows that ABBA significantly improved TIR and significantly reduced both times below- and above-range, compared to BBA. ABBA's performance continued to improve over two months, whereas BBA exhibited only modest changes. This personalised method for adjusting insulin has the potential to further optimise glycaemic control and support people with T1D and T2D in their daily self-management. Our results warrant ABBA to be trialed for the first time in humans.

Reinforcement learning (RL)-based dynamic treatment regimes (DTRs) hold promise for automating complex clinical decision-making, yet their practical deployment remains hindered by the intensive engineering required to inject clinical knowledge and ensure patient safety. Recent advancements in large language models (LLMs) suggest a complementary approach, where implicit prior knowledge and clinical heuristics are naturally embedded through linguistic prompts without requiring environment-specific training. In this study, we rigorously evaluate open-source LLMs as dynamic insulin dosing agents in an in silico Type 1 diabetes simulator, comparing their zero-shot inference performance against small neural network-based RL agents (SRAs) explicitly trained for the task. Our results indicate that carefully designed zero-shot prompts enable smaller LLMs (e.g., Qwen2.5-7B) to achieve comparable or superior clinical performance relative to extensively trained SRAs, particularly in stable patient cohorts. However, LLMs exhibit notable limitations, such as overly aggressive insulin dosing when prompted with chain-of-thought (CoT) reasoning, highlighting critical failure modes including arithmetic hallucination, temporal misinterpretation, and inconsistent clinical logic. Incorporating explicit reasoning about latent clinical states (e.g., meals) yielded minimal performance gains, underscoring the current model's limitations in capturing complex, hidden physiological dynamics solely through textual inference. Our findings advocate for cautious yet optimistic integration of LLMs into clinical workflows, emphasising the necessity of targeted prompt engineering, careful validation, and potentially hybrid approaches that combine linguistic reasoning with structured physiological modelling to achieve safe, robust, and clinically effective decision-support systems.

Managing physiological variables within clinically safe target zones is a central challenge in healthcare, particularly for chronic conditions such as Type 1 Diabetes Mellitus (T1DM). Reinforcement learning (RL) offers promise for personalising treatment, but struggles with the delayed and heterogeneous effects of interventions. We propose a novel RL framework to study and support decision-making in T1DM technologies, such as automated insulin delivery. Our approach captures the complex temporal dynamics of treatment by unifying two control modalities: \textit{impulse control} for discrete, fast-acting interventions (e.g., insulin boluses), and \textit{switching control} for longer-acting treatments and regime shifts. The core of our method is a constrained Markov decision process augmented with physiological state features, enabling safe policy learning under clinical and resource constraints. The framework incorporates biologically realistic factors, including insulin decay, leading to policies that better reflect real-world therapeutic behaviour. While not intended for clinical deployment, this work establishes a foundation for future safe and temporally-aware RL in healthcare. We provide theoretical guarantees of convergence and demonstrate empirical improvements in a stylised T1DM control task, reducing blood glucose level violations from 22.4\% (state-of-the-art) to as low as 10.8\%.

Accurately estimating parameters of physiological models is essential to achieving reliable digital twins. For Type 1 Diabetes, this is particularly challenging due to the complexity of glucose-insulin interactions. Traditional methods based on Markov Chain Monte Carlo struggle with high-dimensional parameter spaces and fit parameters from scratch at inference time, making them slow and computationally expensive. In this study, we propose a Simulation-Based Inference approach based on Neural Posterior Estimation to efficiently capture the complex relationships between meal intake, insulin, and glucose level, providing faster, amortized inference. Our experiments demonstrate that SBI not only outperforms traditional methods in parameter estimation but also generalizes better to unseen conditions, offering real-time posterior inference with reliable uncertainty quantification.

High quality real world datasets are essential for advancing data driven approaches in type 1 diabetes (T1D) management, including personalized therapy design, digital twin systems, and glucose prediction models. However, progress in this area has been limited by the scarcity of publicly available datasets that offer detailed and comprehensive patient data. To address this gap, we present AZT1D, a dataset containing data collected from 25 individuals with T1D on automated insulin delivery (AID) systems. AZT1D includes continuous glucose monitoring (CGM) data, insulin pump and insulin administration data, carbohydrate intake, and device mode (regular, sleep, and exercise) obtained over 6 to 8 weeks for each patient. Notably, the dataset provides granular details on bolus insulin delivery (i.e., total dose, bolus type, correction specific amounts) features that are rarely found in existing datasets. By offering rich, naturalistic data, AZT1D supports a wide range of artificial intelligence and machine learning applications aimed at improving clinical decision making and individualized care in T1D.

Machine Ethics decisions should consider the implications of uncertainty over decisions. Decisions should be made over sequences of actions to reach preferable outcomes long term. The evaluation of outcomes, however, may invoke one or more moral theories, which might have conflicting judgements. Each theory will require differing representations of the ethical situation. For example, Utilitarianism measures numerical values, Deontology analyses duties, and Virtue Ethics emphasises moral character. While balancing potentially conflicting moral considerations, decisions may need to be made, for example, to achieve morally neutral goals with minimal costs. In this paper, we formalise the problem as a Multi-Moral Markov Decision Process and a Multi-Moral Stochastic Shortest Path Problem. We develop a heuristic algorithm based on Multi-Objective AO*, utilising Sven-Ove Hansson's Hypothetical Retrospection procedure for ethical reasoning under uncertainty. Our approach is validated by a case study from Machine Ethics literature: the problem of whether to steal insulin for someone who needs it.

The growing worldwide incidence of diabetes requires more effective approaches for managing blood glucose levels. Insulin delivery systems have advanced significantly, with artificial intelligence (AI) playing a key role in improving their precision and adaptability. AI algorithms, particularly those based on reinforcement learning, allow for personalised insulin dosing by continuously adapting to an individual's responses. Despite these advancements, challenges such as data privacy, algorithm transparency, and accessibility still need to be addressed. Continued progress and validation in AI-driven insulin delivery systems promise to improve therapy outcomes further, offering people more effective and individualised management of their diabetes. This paper presents an overview of current strategies, key challenges, and future directions.

Type 1 Diabetes is a chronic autoimmune condition in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in little to no insulin production. Insulin helps glucose in your blood enter your muscle, fat, and liver cells so they can use it for energy or store it for later use. If insulin is insufficient, it causes sugar to build up in the blood and leads to serious health problems. People with Type 1 Diabetes need synthetic insulin every day. In diabetes management, continuous glucose monitoring is an important feature that provides near real-time blood glucose data. It is useful in deciding the synthetic insulin dose. In this research work, we used machine learning tools, deep neural networks, deep reinforcement learning, and voting and stacking regressors to predict blood glucose levels at 30-min time intervals using the latest DiaTrend dataset. Predicting blood glucose levels is useful in better diabetes management systems. The trained models were compared using several evaluation metrics. Our evaluation results demonstrate the performance of various models across different glycemic conditions for blood glucose prediction. The source codes of this work can be found in: https://github.com/soon-jynn-chu/t1d_bg_prediction

A patient undergoes multiple examinations in each hospital stay, where each provides different facets of the health status. These assessments include temporal data with varying sampling rates, discrete single-point measurements, therapeutic interventions such as medication administration, and images. While physicians are able to process and integrate diverse modalities intuitively, neural networks need specific modeling for each modality complicating the training procedure. We demonstrate that this complexity can be significantly reduced by visualizing all information as images along with unstructured text and subsequently training a conventional vision-text transformer. Our approach, Vision Transformer for irregular sampled Multi-modal Measurements (ViTiMM), not only simplifies data preprocessing and modeling but also outperforms current state-of-the-art methods in predicting in-hospital mortality and phenotyping, as evaluated on 6,175 patients from the MIMIC-IV dataset. The modalities include patient's clinical measurements, medications, X-ray images, and electrocardiography scans. We hope our work inspires advancements in multi-modal medical AI by reducing the training complexity to (visual) prompt engineering, thus lowering entry barriers and enabling no-code solutions for training. The source code will be made publicly available.